ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026
Responsive neurostimulation in children, adolescents, and young Adults-Longitudinal effectiveness and safety.
Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-resistant epilepsy (DRE) remains challenging to treat, and seizure control often fluctuates over time. Responsive neurostimulation (RNS) is increasingly used in pediatric and young adult populations, yet long-term effectiveness and safety data are limited. We evaluated longitudinal seizure control trajectories and safety of RNS in children, adolescents, and young adults treated at our center. Seizure frequency was assessed at approximately 6-month intervals from serial follow-up visits through the most recent follow-up, with each sampled visit categorized by ≥ 50 % (all-responder, AR) or ≥90 % (super-responder, SR) seizure reduction. We examined the persistence and durability of seizure control and used recurrent-event regression to identify clinical modifiers of sustained response. Responder rates improved over time, with 57 % and 75 % of patients achieving AR status at 24 and 47 mean months post-implantation, respectively; corresponding SR rates were 22 % and 33 %. Once achieved, seizure control was typically maintained: the probability of remaining an AR for 24 months was 70 %, and the median proportion of follow-up with sustained response exceeded 85 % across age groups. Concurrent epilepsy surgery favored maintenance of AR status (HR 1.83, p = 0.02), while syndrome-related epilepsies reduced the likelihood of sustained SR status (HR 0.30, p = 0.03). Age at implantation and responder status at 24 months both associated with long-term seizure control. Serious (0.032 events/person-year) and non-serious (0.038 events/person-year) adverse effects were infrequent. RNS provided durable benefit for most, though not all, patients, reflecting the dynamic nature of seizure control. The favorable effectiveness and safety profile support use of RNS in young patients with DRE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.